What to Do When Triptan Monotherapy Fails in Migraine with Brainstem Aura
This protocol addresses migraine with brainstem aura in patients where treatment with a triptan alone did not achieve the expected outcomes — specifically where pain freedom at two hours was not attained, or where headache recurred after an initially effective dose.
Previous Treatment Line — Goals Not Met
The prior acute treatment used 5-HT1B/1D-agonists (triptans). The targets it was expected to reach — freedom from pain 2 hours after administration and adequate control of headache recurrence — were not achieved. This protocol represents the structured next step when triptan monotherapy is insufficient.
Next-Step Approach — Partial Overview
The approach for this scenario moves beyond a single agent. It involves a combination strategy that pairs a triptan with a long-acting anti-inflammatory agent. This combination is selected specifically because it addresses not only the acute pain episode but also reduces the likelihood of headache returning within the critical post-treatment window — something triptan monotherapy alone does not consistently provide.
The full regimen — specific agents, sequencing, and management of recurrence — is available in the structured protocol below.
Clinical Goals
- Freedom from pain 2 hours after administration
- Prevention of headache recurrence within 2–24 hours after treatment
References
DOI: 10.1177/2514183X1882337
- The initial combination of a triptan with a long-acting NSAID (such as naproxen) is more effective than the individual components and can in part prevent the recurrence of migraine attacks.
- In unsatisfactory effectiveness of a triptan, the triptan may be combined with a rapid-acting NSAID.
- The combination of triptans with naproxen is more effective than monotherapy.
- Recurrent headache is defined as a worsening of headache intensity from no headache or mild headache to moderate or severe headache in a period from 2–24 h after the first effective medication application.
View source ↗